GSK’s Tykerb gets priority review

Share this article:
The designation means a decision on Glaxo’s application must come within six months of the drug’s filing date with the FDA, which was Sept. 18. Glaxo is seeking to market Tykerb as a treatment to be used in combination with Roche’s Xeloda for breast cancer that has spread to other parts of the body. Tykerb, if approved, would compete with Roche and Genentech’s rival drug Herceptin. Analysts predict that Tykerb be a $4 billion-a-year seller, depending on how it performs against Herceptin.
Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.